A Phase 1 interventional study of MK-2060 and Placebo in Renal Dialysis and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 10 in phase 1, and was the 5th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.
Drug: MK-2060
Participants will receive a single 20-mg dose of MK-2060 via IV infusion.
Drug: MK-2060
Participants will receive a single 40-mg dose of MK-2060 via IV infusion.
Drug: MK-2060
Participants will receive a single dose of placebo via IV infusion.
Drug: Placebo
Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4)
Drug: MK-2060
Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via IV infusion weekly for 3 weeks (Weeks 2-4)
Drug: Placebo
Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1. Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.
Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
Part 1: Percentage of Participants With Any Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants that experienced an AE was summarized.
Time frame: Up to 164 days
Part 2: Percentage of Participants With Any AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was summarized.
Time frame: Up to 118 days
Part 1: Percentage of Participants With Any Serious Adverse Event
A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.
Time frame: Up to 164 days
Part 2: Percentage of Participants With Any SAE
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.
Time frame: Up to 118 days
Part 1: Percentage of Participants With a Systemic AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.
Time frame: Up to 164 days
Part 2: Percentage of Participants With a Systemic AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.
Time frame: Up to 118 days
Part 1: Percentage of Participants With an Injection-Site AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.
Time frame: Up to 164 days
Part 2: Percentage of Participants With an Injection-Site AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.
Time frame: Up to 118 days
Part 1: Percentage of Participants Discontinuing the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that discontinued the study due to an AE was summarized.
Time frame: Up to 164 days
Part 2: Percentage of Participants Discontinuing Study Drug Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that had study drug discontinued regardless of study completion status was summarized.
Time frame: Up to 4 weeks
Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf)
Plasma samples were collected at pre-specified time points post-dose and AUC0-inf was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150
Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)
Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060
Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150
Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168)
Plasma samples were collected at 168 hours post-dose and C168 was assessed.
Time frame: 168 hours post dose
Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060
Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Part 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060
Plasma samples was collected at pre-specified time points post-dose and t ½ was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Part 1: Plasma Clearance (CL) of MK-2060
Plasma samples were collected at pre-specified time points post-dose and CL was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Part 1: Plasma Volume of Distribution (Vz) of MK-2060
Plasma samples were collected at pre-specified time points post-dose and Vz was assessed.
Time frame: Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose
Part 2: AUC0-168 of MK-2060
Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.
Time frame: Up to 168 hours on Day 1 and Day 22
Part 2: Cmax of MK-2060
Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.
Time frame: Day 1 and Day 22
Part 2: C168 of MK-2060
Plasma samples were collected at 168 hours post-dose and C168 was assessed.
Time frame: 168 hours post dose on Days 1 and 22
Part 2: Tmax of MK-2060
Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.
Time frame: Day 1 and Day 22
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 1
Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.
Time frame: Baseline and 168 hours post-dose (Day 8)
Fold Change From Baseline in aPTT of MK-2060: Part 2
Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.
Time frame: Baseline and Day 8
Male and Female of non-childbearing potential (WONCBP) participants with end-stage renal disease (ESRD) on hemodialysis (HD) between the ages of 18 and 80 years (ages ≥ 40 and ≤ 80 for Part 1 and ≥ 18 and ≤ 80 for Part 2) were enrolled in this study.
| Milestone | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 6 | 7 | 6 | 5 | 0 | 0 |
| Completed | 6 | 7 | 6 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 16 | 5 |
| Completed | 0 | 0 | 0 | 0 | 15 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Unknon | 0 | 0 | 0 | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants that experienced an AE was summarized.
| Percentage of Participants | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Percentage of Participants With Any Adverse Event (AE) | 16.7 | 57.1 | 66.7 | 60.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was summarized.
| Percentage of Participants | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Participants With Any AE | 12.5 | 100.0 |
A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.
| Percentage of Participants | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Percentage of Participants With Any Serious Adverse Event | 0.0 | 0.0 | 16.7 | 0.0 |
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized.
| Percentage of Participants | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Participants With Any SAE | 6.3 | 60.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.
| Percentage of Participants | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Percentage of Participants With a Systemic AE | 0.0 | 0.0 | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath.
| Percentage of Participants | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Participants With a Systemic AE | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.
| Percentage of Participants | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Percentage of Participants With an Injection-Site AE | 0.0 | 0.0 | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling.
| Percentage of Participants | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Participants With an Injection-Site AE | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that discontinued the study due to an AE was summarized.
| Percentage of Participants | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) | Part 1: Placebo |
|---|---|---|---|---|
| Part 1: Percentage of Participants Discontinuing the Study Due to an AE | 0.0 | 0.0 | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that had study drug discontinued regardless of study completion status was summarized.
| Percentage of Participants | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|
| Part 2: Percentage of Participants Discontinuing Study Drug Due to an AE | 0.0 | 40.0 |
Plasma samples were collected at pre-specified time points post-dose and AUC0-inf was assessed.
| hr*nmol/Liter | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf) | 4550 ± 61.2 | 6520 ± 63.4 | 15100 ± 31.7 |
Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.
| hr*nmol/Liter | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168) | 1560 ± 32.5 | 2420 ± 47.0 | 4930 ± 26.8 |
Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.
| nmol/Liter | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060 | 14.8 ± 38.2 | 28.0 ± 49.3 | 61.3 ± 19.3 |
Plasma samples were collected at 168 hours post-dose and C168 was assessed.
| nmol/Liter | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168) | 6.29 ± 41.6 | 9.10 ± 57.7 | 15.8 ± 30.2 |
Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.
| Hours | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060 | 1.13 (0.75 to 12.00) | 0.97 (0.83 to 12.00) | 1.09 (0.90 to 12.00) |
Plasma samples was collected at pre-specified time points post-dose and t ½ was assessed.
| Hours | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060 | 325 ± 88.5 | 422 ± 69.0 | 508 ± 21.7 |
Plasma samples were collected at pre-specified time points post-dose and CL was assessed.
| Liters/hour | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Plasma Clearance (CL) of MK-2060 | 0.0119 ± 61.2 | 0.0207 ± 63.4 | 0.0179 ± 31.7 |
Plasma samples were collected at pre-specified time points post-dose and Vz was assessed.
| Liters | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel A- MK-2060 (40 mg) |
|---|---|---|---|
| Part 1: Plasma Volume of Distribution (Vz) of MK-2060 | 5.56 ± 49.0 | 12.6 ± 65.3 | 13.1 ± 31.2 |
Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed.
| hr*nmol/L | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance |
|---|---|
| Day 1 | 2290 ± 26.8 |
| Day 22 | 9880 ± 28.9 |
Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed.
| nmol/Liter | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance |
|---|---|
| Day 1 | 32.6 ± 32.5 |
| Day 22 | 90.9 ± 30.4 |
Plasma samples were collected at 168 hours post-dose and C168 was assessed.
| nmol/Liter | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance |
|---|---|
| Day 1 | 54.1 ± 42.1 |
| Day 22 | 43.8 ± 30.5 |
Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed.
| Hours | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance |
|---|---|
| Day 1 | 1.00 (0.92 to 47.92) |
| Day 22 | 1.00 (0.00 to 24.00) |
Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.
| Ratio | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel A- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo |
|---|---|---|---|---|
| Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 1 | 1.04 (0.92 to 1.18) | 1.17 (1.06 to 1.30) | 1.52 (1.36 to 1.71) | 1.05 (0.92 to 1.19) |
Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported.
| Ratio | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|
| Fold Change From Baseline in aPTT of MK-2060: Part 2 | 2.46 (1.95 to 3.11) | 0.68 (0.43 to 1.06) |
Collected over Up to 164 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Panel A- MK-2060 (8 mg) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Panel B- MK-2060 (20 mg) | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Part 1: Panel C- MK-2060 (40 mg) | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| Part 1: Placebo | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | 0/16 (0%) | 1/16 (6.3%) | 1/16 (6.3%) |
| Part 2: Placebo | 0/5 (0%) | 3/5 (60%) | 4/5 (80%) |
| Event | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|---|---|---|---|
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/6 | 0/7 | 0/6 | 0/5 | 0/16 | 1/5 |
| PneumoniaInfections and infestations | 0/6 | 0/7 | 0/6 | 0/5 | 0/16 | 1/5 |
| Arteriovenous graft thrombosisInjury, poisoning and procedural complications | 0/6 | 0/7 | 0/6 | 0/5 | 0/16 | 1/5 |
| COVID-19Infections and infestations | 0/6 | 0/7 | 1/6 | 0/5 | 0/16 | 0/5 |
| Myocardial infarctionCardiac disorders | 0/6 | 0/7 | 0/6 | 0/5 | 1/16 | 0/5 |
| Event | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/7 | 0/6 | 1/5 | 0/16 | 2/5 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 0/7 | 2/6 | 0/5 | 0/16 | 0/5 |
| NauseaGastrointestinal disorders | 0/6 | 0/7 | 0/6 | 0/5 | 1/16 | 1/5 |
| ToothacheGastrointestinal disorders | 0/6 | 0/7 | 0/6 | 1/5 | 0/16 | 0/5 |
| COVID-19Infections and infestations | 0/6 | 0/7 | 0/6 | 0/5 | 0/16 | 1/5 |
| Skin abrasionInjury, poisoning and procedural complications | 0/6 | 1/7 | 1/6 | 1/5 | 0/16 | 0/5 |
| Thermal burnInjury, poisoning and procedural complications | 0/6 | 0/7 | 0/6 | 1/5 | 0/16 | 0/5 |
| HeadacheNervous system disorders | 0/6 | 0/7 | 1/6 | 0/5 | 0/16 | 1/5 |
| Arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications | 0/6 | 0/7 | 1/6 | 0/5 | 0/16 | 0/5 |
| SyncopeNervous system disorders | 0/6 | 0/7 | 1/6 | 0/5 | 0/16 | 0/5 |
Seven participants in Part 1 also participated in Part 2. They have been removed from Part 2 listing and counted only once
| Age, Continuous(Years) | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 56.8 ± 5.1 | 61.1 ± 4.3 | 58.2 ± 5.9 | 60.0 ± 7.3 | 54.7 ± 7.0 | 52.5 ± 11.6 | 57.2 ± 6.9 |
| Sex: Female, Male(Participants) | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 4 | 2 | 1 | 2 | 0 | 10 |
| Male | 5 | 3 | 4 | 4 | 8 | 4 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 6 | 7 | 6 | 5 | 8 | 4 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part 1: Panel A- MK-2060 (8 mg) | Part 1: Panel B- MK-2060 (20 mg) | Part 1: Panel C- MK-2060 (40 mg) | Part 1: Placebo | Part 2: MK-2060 25-mg Loading/ 25-mg Maintenance | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 3 | 3 | 8 | 4 | 27 |
| White | 0 | 4 | 3 | 2 | 2 | 0 | 11 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Apr 2019 to primary completion in Dec 2021, 31 months.
Results were first posted in Jun 2024, 2 years 5 months after primary completion.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 31 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-2060